- Home
- NERV vs IMRN Comparison
NERV vs IMRN Comparison
Compare NERV & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- IMRN
- Stock Information
- Founded
- NERV 2007
- IMRN 1994
- Country
- NERV United States
- IMRN Australia
- Employees
- NERV N/A
- IMRN N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- IMRN Health Care
- Exchange
- NERV Nasdaq
- IMRN Nasdaq
- Market Cap
- NERV 10.7M
- IMRN 10.1M
- IPO Year
- NERV 2014
- IMRN N/A
- Fundamental
- Price
- NERV $1.61
- IMRN $1.75
- Analyst Decision
- NERV Hold
- IMRN Strong Buy
- Analyst Count
- NERV 1
- IMRN 1
- Target Price
- NERV $5.00
- IMRN $5.00
- AVG Volume (30 Days)
- NERV 15.1K
- IMRN 13.7K
- Earning Date
- NERV 04-30-2025
- IMRN 04-15-2025
- Dividend Yield
- NERV N/A
- IMRN N/A
- EPS Growth
- NERV N/A
- IMRN N/A
- EPS
- NERV 0.19
- IMRN N/A
- Revenue
- NERV N/A
- IMRN $4,048,286.00
- Revenue This Year
- NERV N/A
- IMRN N/A
- Revenue Next Year
- NERV N/A
- IMRN N/A
- P/E Ratio
- NERV $8.95
- IMRN N/A
- Revenue Growth
- NERV N/A
- IMRN 82.90
- 52 Week Low
- NERV $1.42
- IMRN $1.70
- 52 Week High
- NERV $3.69
- IMRN $3.09
- Technical
- Relative Strength Index (RSI)
- NERV 41.00
- IMRN 41.07
- Support Level
- NERV $1.54
- IMRN $1.73
- Resistance Level
- NERV $1.89
- IMRN $2.09
- Average True Range (ATR)
- NERV 0.11
- IMRN 0.14
- MACD
- NERV 0.00
- IMRN 0.00
- Stochastic Oscillator
- NERV 22.68
- IMRN 10.26
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.